Salesforce Climate Action Plan: Our Journey to Net Zero

Greenhouse gases and rising global temperatures are the most urgent issues facing humanity today; that’s why achieving Net Zero has never been so important.

In this report, Criticaleye Partner Salesforce share their continuous journey towards carbon neutrality and what the approach may look like for other businesses. 

Key takeaways include:
  • Organisations must prioritise reducing carbon emissions as quickly as possible.
  • Ecosystem restoration is a great way to sequester carbon from the atmosphere.
  • Education and mobilisation are essential to drive climate action.
  • Innovation is needed to transform and expedite the path to decarbonisation.
 




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
Destination Net Zero

The race to Net Zero is well underway, but how fast are companies really progressing? Criticaleye Partner Accenture’s Destination Net Zero report sheds light on this question. Drawing on data from the world&r...

Click here to download this insight
Rolling Back on DEI: The Lega...

With the introduction of new Executive Orders in the USA titled “Ending Illegal Discrimination and Restoring Merit-Based Opportunity”, Diversity, Equity and Inclusion (DEI) has sparked a global discussion fo...

Click here to download this insight
The Role of Automation in Ret...

Retail automation has become an essential part of the modern shopping experience. As technology advances, retail leaders are deliberating whether checkouts should be fully automated or merely assisted. This report by Cr...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 162




Amazon UK Salesforce Workday Hitachi Solutions Google Royal London Group Palo Alto Networks AlixPartners LDC Concentrix NATS Experian Legal & General Investment Management Drax Group plc London Stock Exchange Group Lightsource bp Rolls-Royce Eightfold AI IBM Consulting Redwood Bank E.ON UK FTSE Women Leaders Review Accenture GlaxoSmithKline plc